Blood thinner to prevent clots in kidney disease
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether the blood thinner rivaroxaban can prevent dangerous blood clots in people with a kidney condition called membranous nephropathy who have low albumin levels and are at high risk for clots.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with membranous nephropathy (a kidney disease) by a biopsy.
- You have nephrotic syndrome (high protein in urine, swelling) and low blood albumin (less than 25 g/L).
- Your kidneys are working normally (normal creatinine clearance).
- You have not had a previous blood clot (like in your leg, kidney, or lung).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the body processes a certain type of blood thinner (Xa factor inhibitors) to help doctors find the right dose for each person. If you have a blood clot in your lungs and are on long-term treatment, this trial might help improve your care.
This study tests whether a lower dose of the blood thinner rivaroxaban is safe for people with kidney failure on dialysis who do not already need blood thinners. The goal is to find a way to prevent blood clots and strokes with less risk of bleeding.
This trial compares two types of blood thinners (vitamin K antagonists and factor Xa inhibitors) versus no blood thinner in people with atrial fibrillation who are on dialysis or have very advanced kidney disease. It aims to see which option is safest and most effective for preventing strokes and bleeds.
This trial compares apixaban or rivaroxaban (blood thinners) against aspirin to prevent future clot-related complications in people with certain bone marrow diseases (PV, ET, or pre-PMF) that have a specific JAK2 mutation. It may help lower the risk of clots, but it also carefully considers bleeding risk.
This study compares two ways to manage atrial fibrillation (an irregular heartbeat) in people on dialysis. One approach uses a blood thinner called apixaban, and the other does not use blood thinners. The goal is to see which approach better prevents strokes and bleeding.
This trial tests how to use a blood thinner in people after a recent heart attack who have a clot in the left heart chamber confirmed by heart MRI. It may help lower the risk of the clot causing serious complications, but it also requires careful bleeding-safety screening.
Hear when a new Idiopathic Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.